Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer

Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer Curr Breast Cancer Rep (2017) 9:183–187 DOI 10.1007/s12609-017-0250-y CLINICAL TRIALS (PF PEDDI, SECTION EDITOR) Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer 1 1 O. H. Vyas & V. G. Kaklamani Published online: 14 July 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Breast cancer Endocrine therapy Extended . . . Purpose of Review As adjuvant therapy for early-stage, endocrine therapy Aromatase inhibitors Adjuvant therapy hormone receptor-positive breast cancer has improved, late Hormone-positive breast cancer recurrences have become a significant issue. Endocrine therapies such as tamoxifen and aromatase inhibitors play a central role in reducing the risk of recurrence of hormone- Introduction positive breast cancers. However, the continued risk of breast cancer recurrence even with 5 years of adjuvant In 1896, Dr. George Beatson reported three cases of advanced AI therapy has led to interest in extended therapy. This breast cancer that improved after oophorectomy, the first re- review intends to discuss and analyze recent trials that port of successful endocrine therapy for breast cancer [1]. have reported results with extending AI therapy beyond Since then, the management of breast cancer has become in- 5 years of treatment. creasingly complex, with selective http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer

Loading next page...
 
/lp/springer_journal/evaluating-the-role-of-extended-aromatase-inhibitor-therapy-in-early-g2BE2yqFes
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
D.O.I.
10.1007/s12609-017-0250-y
Publisher site
See Article on Publisher Site

Abstract

Curr Breast Cancer Rep (2017) 9:183–187 DOI 10.1007/s12609-017-0250-y CLINICAL TRIALS (PF PEDDI, SECTION EDITOR) Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer 1 1 O. H. Vyas & V. G. Kaklamani Published online: 14 July 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Breast cancer Endocrine therapy Extended . . . Purpose of Review As adjuvant therapy for early-stage, endocrine therapy Aromatase inhibitors Adjuvant therapy hormone receptor-positive breast cancer has improved, late Hormone-positive breast cancer recurrences have become a significant issue. Endocrine therapies such as tamoxifen and aromatase inhibitors play a central role in reducing the risk of recurrence of hormone- Introduction positive breast cancers. However, the continued risk of breast cancer recurrence even with 5 years of adjuvant In 1896, Dr. George Beatson reported three cases of advanced AI therapy has led to interest in extended therapy. This breast cancer that improved after oophorectomy, the first re- review intends to discuss and analyze recent trials that port of successful endocrine therapy for breast cancer [1]. have reported results with extending AI therapy beyond Since then, the management of breast cancer has become in- 5 years of treatment. creasingly complex, with selective

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Jul 14, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off